Version 1
: Received: 5 March 2020 / Approved: 7 March 2020 / Online: 7 March 2020 (16:28:05 CET)
How to cite:
Omotuyi, O. I.; Nash, O.; Ajiboye, B. O.; Metibemu, D. S.; Oyinloye, B. E.; Adelakun, N. S.; Hurdayal, R.; Aruleba, R. T.; Kappo, A. P. Darunavir Disrupts Critical Nodes in Metastable 2019-nCoV-RBD/ACE-2 Complex. Preprints2020, 2020030125. https://doi.org/10.20944/preprints202003.0125.v1
Omotuyi, O. I.; Nash, O.; Ajiboye, B. O.; Metibemu, D. S.; Oyinloye, B. E.; Adelakun, N. S.; Hurdayal, R.; Aruleba, R. T.; Kappo, A. P. Darunavir Disrupts Critical Nodes in Metastable 2019-nCoV-RBD/ACE-2 Complex. Preprints 2020, 2020030125. https://doi.org/10.20944/preprints202003.0125.v1
Omotuyi, O. I.; Nash, O.; Ajiboye, B. O.; Metibemu, D. S.; Oyinloye, B. E.; Adelakun, N. S.; Hurdayal, R.; Aruleba, R. T.; Kappo, A. P. Darunavir Disrupts Critical Nodes in Metastable 2019-nCoV-RBD/ACE-2 Complex. Preprints2020, 2020030125. https://doi.org/10.20944/preprints202003.0125.v1
APA Style
Omotuyi, O. I., Nash, O., Ajiboye, B. O., Metibemu, D. S., Oyinloye, B. E., Adelakun, N. S., Hurdayal, R., Aruleba, R. T., & Kappo, A. P. (2020). Darunavir Disrupts Critical Nodes in Metastable 2019-nCoV-RBD/ACE-2 Complex. Preprints. https://doi.org/10.20944/preprints202003.0125.v1
Chicago/Turabian Style
Omotuyi, O. I., Raphael Taiwo Aruleba and Abidemi Paul Kappo. 2020 "Darunavir Disrupts Critical Nodes in Metastable 2019-nCoV-RBD/ACE-2 Complex" Preprints. https://doi.org/10.20944/preprints202003.0125.v1
Abstract
The transnational spread of coronavirus (2019-nCoV) first detected in Wuhan is causing global panic; thus, accelerated research into clinical intervention is of high necessity. The spike glycoprotein structure has been resolved, and its affinity to human angiotensin-converting enzyme 2 (ACE-2) has been experimentally validated. Here, using computational methods, a metastable conformation of 2019-nCoV-RBD/ACE-2 complex has been revealed and FDA-database of approved drugs have been docked into the interface. Darunavir has been discovered as high ligand affinity candidate capable of disrupting communication between 2019-nCoV-RBD and ACE-2. Darunavir, in addition to its previously known anti-HIV protease inhibitor is now repurposeable for the treatment 2019-nCoV disease acting via disruption of cellular recognition, binding and invasion.
Keywords
2019-nCoV; Darunavir; ACE-2; Receptor Binding Domain; Metastable Conformation; FDA database
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.